Hernández GR, Jiménez HJ, Sánchez CJ

Language: Spanish
References: 28
Page: 241-246
PDF size: 251.94 Kb.

ABSTRACT

Introduction. The incidence of Metabolic Syndrome in postmenopausal patients and determine the metabolic changes and alterations at increased cardiovascular morbidity and mortality. Objective. To determine the prevalence of Metabolic Syndrome in postmenopausal patients of the Gynecology Service. Material and methods. We performed a observational, descriptive study of July to December 2007 in the Service of Gynecology at Hospital Juarez de Mexico, where we studied 60 patients who are postmenopausal timely diagnosis Metabolic Syndrome. Results. The average age of 60 patients was 50.2 years, who were appreciate central obesity, finding an average of 88 cm, with standard deviation of 8.79 and frequency of central obesity 58%. Hypertriglyceridemia in 50% of patients, with an average of 167 mg/dL with standard deviation of 75.7. Determination of HDL with an average of 57.8 mg/dL, and standard deviation of 33.1 with a 48% decline. With regard to systemic blood pressure was found that systolic pressure was normal at present 15%, while the diastolic in 8% of patients. In relation to glucose was found altered in 12% of patients with an average of 94.5 mg/dL. Finally the diagnosis of Metabolic Syndrome taking into account the ATP III criteria document in 46.6%. With higher prevalence of obesity and central dyslipidemia. Conclusion. It could say that among postmenopausal patients there is a high frequency of Metabolic Syndrome, using the ATP III criteria.

REFERENCES

1. Trejo-Gutiérrez JF. Epidemiología del Síndrome Metabólico y Diabetes Mellitus tipo 2: ¿El diluvio que viene? Arch Cardiol Mex 2004; 74(Supl. 29): S267-70.

2. Lozano-Asencio R, Escamilla-Cejudo JA, Escobedo de la Peña J, López-Cervantes M. Tendencia de la mortalidad por cardiopatía isquémica en México de 1950 a 1985. Salud Pub Mex 1990; 32: 405-15.

3. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-9.

4. Anderson EA, Mark AL. The vasodilator action of insulin: implications for the insulin hypothesis of hypertension. Hypertension 1993; 21: 136-41.

5. Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 1997; 30: 928-31.

6. Eckel RH, Grundy SM, Zimmet PZ. The Metabolic Syndrome. Lancet 2005; 365: 1415-28.

7. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system. N Eng J Med 1996; 334: 374-81.

8. Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. Endocrinol Metab Clin North Am 2003; 32: 855- 67.

9. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985; 313: 756-61.

10. Giovannone B, Scaldaferri ML, Federici M, Porzio O, Lauro D, Fusco A, et al. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab Res Rev 2000; 16: 434-41.

11. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-Kinase regulates cell signaling and survival. Mol Cell Biol 2002; 22: 965-77.

12. Pirola L, Johnston AM, Van Obberghen E. Modulation of insulin action. Diabetologia 2004; 47: 170-84.

13. Flakoll PJ, Carlson MG, Cherrington AD. Acción fisiológica de la insulina. En: Le Roith D, Taylor SI, Olefsky JM (eds.). Diabetes Mellitus, Fundamentos y Clínica. 2 Ed. México: McGraw-Hill; 2003.

14. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2001; 2: 282-6.

15. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27: S53-5.

16. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 2000; 24: S23-7.

17. Fusshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-603.

18. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998; 47: 913-17.

19. Brady MJ. IRS2 takes center stage in the development of type 2 diabetes. J Clin Invest 2004; 114: 886-8.

20. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 95: 763-70.

21. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science 1993; 259: 87-91.

22. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor. Cytokine Growth Factor Rev 2003; 14: 447-55.

23. Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 2002; 440: 213-21.

24. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and Metabolic Syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.

25. Chandran M, Phillips SA, Ciaraldi T, Henry RR, et al. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-50.

26. Scheffer P. American Diabetes Association Scientific Sessions Outstanding Scientific Achievement Lecture 2005: Adipose tissue, from fat storage to endocrine organ.

27. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetics metabolism effects. Nature 2003; 423: 762-9.

28. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293-300.